Search research articles
Contact Us
Filters
Showing results (101-110 of 109) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 109 results.
Oncogene
|
July 4, 2012
Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms
M Eißmann, I M Melzer, S B M Fernández, et al.
Leukemia
|
May 15, 2015
p53-dependent non-coding RNA networks in chronic lymphocytic leukemia
C J Blume, A Hotz-Wagenblatt, J Hüllein, et al.
Oncogene
|
September 1, 2009
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis
A Seckinger, T Meissner, J Moreaux, et al.
Leukemia
|
March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
E K Mai, U Bertsch, J Dürig, et al.
Bone Marrow Transplantation
|
May 16, 2017
Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial
S Huhn, N Weinhold, J Nickel, et al.
Leukemia
|
December 28, 2016
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma
M I da Silva Filho, A Försti, N Weinhold, et al.
Genomics
|
September 15, 1996
Mapping human telomere regions with YAC and P1 clones: chromosome-specific markers for 27 telomeres including 149 STSs and 24 polymorphisms for 14 proterminal regions
A Vocero-Akbani, C Helms, J C Wang, et al.
Leukemia
|
February 16, 2017
Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis
M Ratnaparkhe, M Hlevnjak, T Kolb, et al.
Leukemia
|
August 2, 2017
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
H Goldschmidt, H M Lokhorst, E K Mai, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 109) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 109 results.
Oncogene
|
July 4, 2012
Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms
M Eißmann, I M Melzer, S B M Fernández, et al.
Leukemia
|
May 15, 2015
p53-dependent non-coding RNA networks in chronic lymphocytic leukemia
C J Blume, A Hotz-Wagenblatt, J Hüllein, et al.
Oncogene
|
September 1, 2009
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis
A Seckinger, T Meissner, J Moreaux, et al.
Leukemia
|
March 20, 2015
Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma
E K Mai, U Bertsch, J Dürig, et al.
Bone Marrow Transplantation
|
May 16, 2017
Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial
S Huhn, N Weinhold, J Nickel, et al.
Leukemia
|
December 28, 2016
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma
M I da Silva Filho, A Försti, N Weinhold, et al.
Genomics
|
September 15, 1996
Mapping human telomere regions with YAC and P1 clones: chromosome-specific markers for 27 telomeres including 149 STSs and 24 polymorphisms for 14 proterminal regions
A Vocero-Akbani, C Helms, J C Wang, et al.
Leukemia
|
February 16, 2017
Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis
M Ratnaparkhe, M Hlevnjak, T Kolb, et al.
Leukemia
|
August 2, 2017
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
H Goldschmidt, H M Lokhorst, E K Mai, et al.
Page
of 11